Soleno Therapeutics receives FDA approval for VYKAT XR to treat hyperphagia in Prader-Willi Syndrome

From Nasdaq: 2025-03-26 21:35:00

The FDA has approved Soleno Therapeutics’ VYKAT XR for treating hyperphagia in individuals with Prader-Willi syndrome. The extended-release tablets will be available in the U.S. starting April 2025. Soleno also launched Soleno One, a patient support program. The FDA approval was based on a successful Phase 3 study showing the efficacy of VYKAT XR in reducing hyperphagia. Individuals on the medication experienced significant improvement compared to those on placebo. This marks a significant development in the treatment of Prader-Willi syndrome. Visit rttnews.com for more health news.



Read more at Nasdaq: Soleno Therapeutics Gets FDA Approval For VYKAT XR To Treat Hyperphagia In Prader-Willi Syndrome